Glück Conviction Score™ ⓘ
KPTI
Karyopharm Therapeutics Inc.
ⓘ
Eingeschränkte Aussagekraft — erst 66 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Niedrig
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
76,0
29 neu, 37 erhöht, 65,8M $ netto
Aktivist
49,5
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 8.55 | +11.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 7.24 | +31.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 8.88 | EMA50: 8.54 | |
| MACD-Histogramm | Bullisch | 10 % | 0.022 | Bullisch | |
| RSI(14) | Neutral | 10 % | 58.9 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 64.0 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 25.3 | +DI: 32.2 / −DI: 13.3 | |
| Z-Score(60) | Neutral | 5 % | 1.11 | In Range | |
| 52W-Position | Bullisch | 5 % | 90.7 % | Hoch 10.09 / Tief 3.77 | |
| Bollinger(20,2σ) | Neutral | 5 % | 79.6 % | Upper 10.06 / Mid 8.68 / Lower 7.30 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.0486 | R²=0.47 / annualisiert +150.6 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Rangwala Reshma | Officer, EVP & Chief Medical Officer | Open Market Sale | -408 | 9,50 | -3.876,00 | -28,4% | |
| 2026-05-14 | Mano Michael | Officer, EVP, CLO&Secretary | Open Market Sale | -266 | 9,50 | -2.527,00 | -18,5% | |
| 2026-05-14 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -403 | 9,50 | -3.828,50 | -28,0% | |
| 2026-05-14 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -2.203 | 9,50 | -20.928,50 | -153,1% | |
| 2026-05-14 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -324 | 9,50 | -3.078,00 | -22,5% | |
| 2026-05-14 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -53 | 9,50 | -503,50 | -3,7% | |
| 2026-04-21 | Rangwala Reshma | Officer, EVP & Chief Medical Officer | Open Market Sale | -449 | 8,94 | -4.014,06 | -29,4% | |
| 2026-03-02 | Mano Michael | Officer, EVP, CLO&Secretary | Open Market Sale | -3.526 | 9,41 | -33.177,90 | -242,7% | |
| 2026-03-02 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -4.604 | 9,41 | -43.321,34 | -316,9% | |
| 2026-03-02 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -12.361 | 9,41 | -116.310,83 | -850,8% | |
| 2026-03-02 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -5.101 | 9,41 | -47.997,86 | -351,1% | |
| 2026-03-02 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -559 | 9,41 | -5.259,91 | -38,5% | |
| 2026-03-02 | Rangwala Reshma | Officer, EVP & Chief Medical Officer | Open Market Sale | -5.066 | 9,41 | -47.668,53 | -348,7% | |
| 2026-02-17 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -378 | 8,63 | -3.262,14 | -23,9% | |
| 2026-02-03 | Macomber Lori | Officer, EVP, CFO & Treasurer | Open Market Sale | -1.626 | 6,30 | -10.243,80 | -74,9% | |
| 2026-01-28 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -50 | 7,03 | -351,50 | -2,6% | |
| 2026-01-21 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -265 | 5,96 | -1.579,40 | -11,6% | |
| 2025-10-01 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -362 | 6,30 | -2.279,15 | -16,7% | |
| 2025-09-15 | Rangwala Reshma | Officer, EVP & Chief Medical Officer | Open Market Sale | -408 | 6,43 | -2.623,44 | -19,2% | |
| 2025-09-15 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -325 | 6,43 | -2.089,75 | -15,3% | |
| 2025-09-15 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -1.257 | 6,43 | -8.082,51 | -59,1% | |
| 2025-09-15 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -23 | 6,43 | -147,89 | -1,1% | |
| 2025-09-15 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -401 | 6,43 | -2.578,43 | -18,9% | |
| 2025-09-15 | Mano Michael | Officer, SVP, General Counsel&Secretary | Open Market Sale | -234 | 6,43 | -1.504,62 | -11,0% | |
| 2025-09-03 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -12 | 6,78 | -81,36 | -0,6% | |
| 2025-07-29 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -191 | 4,37 | -834,67 | -6,1% | |
| 2025-07-22 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -238 | 4,00 | -952,00 | -7,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 2.573.435 | 544.554 | 2.028.881 | 14.334.033 | Aufgestockt | +372,6% | |
| Commodore Capital LP | 1.950.000 | 0 | 1.950.000 | 10.861.500 | Neu | +100,0% | |
| RA CAPITAL MANAGEMENT, L.P. | 1.917.354 | 0 | 1.917.354 | 10.679.662 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.806.322 | 421.322 | 1.385.000 | 10.061.214 | Aufgestockt | +328,7% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.315.038 | 834.898 | 480.140 | 7.324.762 | Aufgestockt | +57,5% | |
| Opaleye Management Inc. | 930.000 | 0 | 930.000 | 6.844.800 | Neu | +100,0% | |
| Caption Management, LLC | 1.181.900 | 0 | 1.181.900 | 6.583.183 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 947.579 | 0 | 947.579 | 5.278.015 | Neu | +100,0% | |
| Catalio Capital Management, LP | 897.709 | 142.984 | 754.725 | 5.000.239 | Aufgestockt | +527,8% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 750.410 | 144.628 | 605.782 | 4.179.784 | Aufgestockt | +418,9% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 739.745 | 0 | 739.745 | 4.120.380 | Neu | +100,0% | |
| VANGUARD GROUP INC | 559.619 | 0 | 559.619 | 4.118.796 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 665.127 | 401.619 | 263.508 | 3.704.757 | Aufgestockt | +65,6% | |
| JANE STREET GROUP, LLC | 593.701 | 91.333 | 502.368 | 3.306.914 | Aufgestockt | +550,0% | |
| MILLENNIUM MANAGEMENT LLC | 511.571 | 0 | 511.571 | 2.849.450 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 507.500 | 135.509 | 371.991 | 2.826.775 | Aufgestockt | +274,5% | |
| Affinity Asset Advisors, LLC | 500.000 | 889.575 | -389.575 | 2.785.000 | Reduziert | -43,8% | |
| Avidity Partners Management LP | 463.741 | 134.566 | 329.175 | 2.583.037 | Aufgestockt | +244,6% | |
| Soleus Capital Management, L.P. | 440.000 | 440.000 | 0 | 2.450.800 | Unverändert | 0,0% | |
| SIMPLEX TRADING, LLC | 427.600 | 173.468 | 254.132 | 2.381.732 | Aufgestockt | +146,5% | |
| BRAIDWELL LP | 303.370 | 0 | 303.370 | 2.232.803 | Neu | +100,0% | |
| Exome Asset Management LLC | 295.541 | 0 | 295.541 | 2.175.182 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 276.881 | 0 | 276.881 | 2.037.844 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 341.936 | 50.000 | 291.936 | 1.904.584 | Aufgestockt | +583,9% | |
| Boxer Capital Management, LLC | 302.536 | 252.536 | 50.000 | 1.685.126 | Aufgestockt | +19,8% | |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 300.000 | 0 | 300.000 | 1.671.000 | Neu | +100,0% | |
| Eversept Partners, LP | 299.974 | 0 | 299.974 | 1.670.855 | Neu | +100,0% | |
| ACORN CAPITAL ADVISORS, LLC | 287.826 | 0 | 287.826 | 1.603.191 | Neu | +100,0% | |
| Jump Financial, LLC | 262.146 | 53.816 | 208.330 | 1.460.153 | Aufgestockt | +387,1% | |
| Trexquant Investment LP | 257.903 | 41.733 | 216.170 | 1.436.520 | Aufgestockt | +518,0% | |
| Ally Bridge Group (NY) LLC | 250.000 | 0 | 250.000 | 1.392.500 | Neu | +100,0% | |
| BlackRock, Inc. | 244.899 | 247.558 | -2.659 | 1.364.087 | Reduziert | -1,1% | |
| DIADEMA PARTNERS LP | 241.300 | 0 | 241.300 | 1.344.041 | Neu | +100,0% | |
| Brevan Howard Capital Management LP | 212.367 | 0 | 212.367 | 1.182.884 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 206.133 | 187.734 | 18.399 | 1.148.848 | Aufgestockt | +9,8% | |
| UBS Group AG | 194.017 | 88.455 | 105.562 | 1.080.675 | Aufgestockt | +119,3% | |
| BALYASNY ASSET MANAGEMENT L.P. | 170.748 | 0 | 170.748 | 951.066 | Neu | +100,0% | |
| SILVERBACK ASSET MANAGEMENT LLC | 165.000 | 40.000 | 125.000 | 919.050 | Aufgestockt | +312,5% | |
| XTX Topco Ltd | 164.443 | 11.904 | 152.539 | 915.948 | Aufgestockt | +1281,4% | |
| TWO SIGMA INVESTMENTS, LP | 151.232 | 148.793 | 2.439 | 842.362 | Aufgestockt | +1,6% | |
| MARSHALL WACE, LLP | 128.451 | 128.451 | 0 | 715.472 | Unverändert | 0,0% | |
| Walleye Capital LLC | 95.672 | 0 | 95.672 | 704.146 | Neu | +100,0% | |
| TWO SIGMA ADVISERS, LP | 89.729 | 0 | 89.729 | 660.405 | Neu | +100,0% | |
| Engineers Gate Manager LP | 112.432 | 0 | 112.432 | 626.246 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 105.414 | 59.914 | 45.500 | 587.156 | Aufgestockt | +75,9% | |
| Tetragon Partners GP Ltd | 102.984 | 0 | 102.984 | 573.621 | Neu | +100,0% | |
| Birchview Capital, LP | 83.952 | 0 | 83.952 | 467.613 | Neu | +100,0% | |
| Context Capital Management, LLC | 62.995 | 0 | 62.995 | 463.643 | Neu | +100,0% | |
| STATE STREET CORP | 80.742 | 58.942 | 21.800 | 449.733 | Aufgestockt | +37,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 79.081 | 57.212 | 21.869 | 440.481 | Aufgestockt | +38,2% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 2.573.435 | 544.554 | +372,6% | 14.334.033 | 10,96 |
| Commodore Capital LP | 1.950.000 | 0 | +100,0% | 10.861.500 | 8,31 |
| RA CAPITAL MANAGEMENT, L.P. | 1.917.354 | 0 | +100,0% | 10.679.662 | 8,17 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.806.322 | 421.322 | +328,7% | 10.061.214 | 7,70 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.315.038 | 834.898 | +57,5% | 7.324.762 | 5,60 |
| Caption Management, LLC | 1.181.900 | 0 | +100,0% | 6.583.183 | 5,04 |
| GOLDMAN SACHS GROUP INC | 947.579 | 0 | +100,0% | 5.278.015 | 4,04 |
| Catalio Capital Management, LP | 897.709 | 142.984 | +527,8% | 5.000.239 | 3,82 |
| BOOTHBAY FUND MANAGEMENT, LLC | 750.410 | 144.628 | +418,9% | 4.179.784 | 3,20 |
| VANGUARD CAPITAL MANAGEMENT LLC | 739.745 | 0 | +100,0% | 4.120.380 | 3,15 |
| GROUP ONE TRADING LLC | 665.127 | 401.619 | +65,6% | 3.704.757 | 2,83 |
| JANE STREET GROUP, LLC | 593.701 | 91.333 | +550,0% | 3.306.914 | 2,53 |
| MILLENNIUM MANAGEMENT LLC | 511.571 | 0 | +100,0% | 2.849.450 | 2,18 |
| CITADEL ADVISORS LLC | 507.500 | 135.509 | +274,5% | 2.826.775 | 2,16 |
| Affinity Asset Advisors, LLC | 500.000 | 889.575 | -43,8% | 2.785.000 | 2,13 |
| Avidity Partners Management LP | 463.741 | 134.566 | +244,6% | 2.583.037 | 1,98 |
| Soleus Capital Management, L.P. | 440.000 | 440.000 | 0,0% | 2.450.800 | 1,87 |
| SIMPLEX TRADING, LLC | 427.600 | 173.468 | +146,5% | 2.381.732 | 1,82 |
| ADAR1 Capital Management, LLC | 341.936 | 50.000 | +583,9% | 1.904.584 | 1,46 |
| Boxer Capital Management, LLC | 302.536 | 252.536 | +19,8% | 1.685.126 | 1,29 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 84 | 26,9 | 140 |
| 31.12.2025 | ✓ | 69 | 11,4 | 68 |
| 30.09.2025 | ✓ | 61 | 125,7 | 129 |
| 30.06.2025 | ✓ | 57 | 126,3 | 111 |
| 31.03.2025 | ✓ | 54 | 23,4 | 29 |
| 31.12.2024 | ✓ | 90 | 84,3 | 56 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Opaleye Management Inc. | 930.000 | 6.844.800 |
| Soleus Capital Management, L.P. | 440.000 | 3.238.400 |
| AMERIPRISE FINANCIAL INC | 276.881 | 2.037.844 |
| Boxer Capital Management, LLC | 252.536 | 1.858.665 |
| TWO SIGMA INVESTMENTS, LP | 148.793 | 1.095.116 |
| BOOTHBAY FUND MANAGEMENT, LLC | 144.628 | 1.064.462 |
| Walleye Capital LLC | 95.672 | 704.146 |
| TWO SIGMA ADVISERS, LP | 89.729 | 660.405 |
| Quadrature Capital Ltd | 59.708 | 439.451 |
| Connor, Clark & Lunn Investment Management Ltd. | 57.212 | 421.080 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 1.491.409 | 790.417 | +112.8 % | 10.977 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 834.898 | 552.859 | +196.0 % | 6.144.849 |
| Ikarian Capital, LLC | 544.554 | 517.297 | +1897.9 % | 4.007.918 |
| GROUP ONE TRADING LLC | 401.619 | 198.983 | +98.2 % | 2.955.916 |
| VANGUARD GROUP INC | 559.619 | 151.397 | +37.1 % | 4.118.796 |
| GEODE CAPITAL MANAGEMENT, LLC | 187.734 | 94.445 | +101.2 % | 1.381.872 |
| SIMPLEX TRADING, LLC | 173.468 | 92.806 | +115.1 % | 1.276.724 |
| JANE STREET GROUP, LLC | 91.333 | 78.433 | +608.0 % | 672.211 |
| Context Capital Management, LLC | 62.995 | 54.124 | +610.1 % | 463.643 |
| ROYAL BANK OF CANADA | 58.000 | 51.266 | +761.3 % | 427.000 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| BRAIDWELL LP | 303.370 | -48.178.630 | -99.4 % | 2.232.803 |
| Affinity Asset Advisors, LLC | 889.575 | -14.518.025 | -94.2 % | 6.547.272 |
| Exome Asset Management LLC | 295.541 | -1.752.559 | -85.6 % | 2.175.182 |
| JPMORGAN CHASE & CO | 1.741 | -1.215.709 | -99.9 % | 12.814 |
| MORGAN STANLEY | 8.858 | -16.908 | -65.6 % | 65.194 |
| RENAISSANCE TECHNOLOGIES LLC | 59.914 | -4.800 | -7.4 % | 440.967 |
| Belvedere Trading LLC | 12.300 | -2.763 | -18.3 % | 90.528 |
| XTX Topco Ltd | 11.904 | -2.498 | -17.3 % | 87.613 |
| CITIGROUP INC | 1 | -512 | -99.8 % | 7 |
| OSAIC HOLDINGS, INC. | 282 | -64 | -18.5 % | 2.076 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 05.06.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 6,60 % | 1.539.147 | -5,20 pp | |
| 15.05.2026 | ACORN BIOVENTURES, L.P. | Passiv (13G) | 2,80 % | 637.608 | Neu | |
| 15.05.2026 | ACORN BIOVENTURES 2, L.P. | Passiv (13G) | 3,90 % | 880.505 | Neu | |
| 15.05.2026 | Acorn Capital Advisors GP 2, LLC | Passiv (13G) | 3,90 % | 880.505 | Neu | |
| 15.05.2026 | ACORN CAPITAL ADVISORS GP, LLC | Passiv (13G) | 2,80 % | 637.608 | Neu | |
| 15.05.2026 | Anders Hove | Passiv (13G) | 6,70 % | 1.518.113 | Neu | |
| 15.05.2026 | Ikarian Capital, LLC | Passiv (13G) | Ausstieg | 0 | Neu | |
| 15.05.2026 | Neil Shahrestani | Passiv (13G) | Ausstieg | 0 | Neu | |
| 14.05.2026 | Affinity Asset Advisors, LLC | Passiv (13G/A) | 8,60 % | 2.073.517 | 0,00 pp | |
| 14.05.2026 | Michael Cho | Passiv (13G/A) | 8,60 % | 2.073.517 | 0,00 pp | |
| 13.05.2026 | Robert Atchinson | Passiv (13G) | 8,08 % | 1.821.736 | +5,70 pp | |
| 13.05.2026 | Phillip Gross | Passiv (13G) | 8,08 % | 1.821.736 | +5,70 pp | |
| 13.05.2026 | Adage Capital Management, L.P. | Passiv (13G) | 8,08 % | 1.821.736 | +5,70 pp | |
| 12.05.2026 | GOLDMAN SACHS & CO. LLC | Passiv (13G) | 5,10 % | 991.364 | Neu | |
| 12.05.2026 | THE GOLDMAN SACHS GROUP, INC. | Passiv (13G) | 5,10 % | 991.364 | Neu | |
| 11.05.2026 | Opaleye, L.P. | Passiv (13G/A) | 2,67 % | 619.089 | -6,81 pp | |
| 11.05.2026 | Opaleye Management Inc. | Passiv (13G/A) | 2,67 % | 619.089 | -6,81 pp | |
| 11.05.2026 | James Silverman | Passiv (13G/A) | 2,67 % | 619.089 | -6,81 pp | |
| 13.04.2026 | Israel A. Englander | Passiv (13G/A) | 2,30 % | 511.571 | -3,20 pp | |
| 13.04.2026 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 1,90 % | 423.982 | -3,50 pp | |
| 13.04.2026 | Millennium Management LLC | Passiv (13G/A) | 2,30 % | 511.571 | -3,20 pp | |
| 13.04.2026 | Millennium Group Management LLC | Passiv (13G/A) | 2,30 % | 511.571 | -3,20 pp | |
| 02.04.2026 | Commodore Capital LP | Passiv (13G) | 9,90 % | 1.950.000 | Neu | |
| 02.04.2026 | Commodore Capital Master LP | Passiv (13G) | 9,90 % | 1.950.000 | Neu | |
| 02.04.2026 | Michael Kramarz | Passiv (13G) | 9,90 % | 1.950.000 | Neu | |
| 02.04.2026 | Robert Egen Atkinson | Passiv (13G) | 9,90 % | 1.950.000 | Neu | |
| 02.04.2026 | Rajeev Shah | Passiv (13G) | 9,90 % | 2.078.913 | Neu | |
| 02.04.2026 | Peter Kolchinsky | Passiv (13G) | 9,90 % | 2.078.913 | Neu | |
| 02.04.2026 | RA Capital Healthcare Fund, L.P. | Passiv (13G) | 9,90 % | 2.078.913 | Neu | |
| 02.04.2026 | RA Capital Management, L.P. | Passiv (13G) | 9,90 % | 2.078.913 | Neu | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 11,80 % | 2.244.421 | -2,00 pp | |
| 12.02.2026 | Robert Atchinson | Passiv (13G/A) | 2,38 % | 436.736 | -2,80 pp | |
| 12.02.2026 | Adage Capital Management, L.P. | Passiv (13G/A) | 2,38 % | 436.736 | -2,80 pp | |
| 12.02.2026 | Phillip Gross | Passiv (13G/A) | 2,38 % | 436.736 | -2,80 pp | |
| 10.02.2026 | Israel A. Englander | Passiv (13G) | 5,50 % | 1.008.662 | +5,50 pp | |
| 10.02.2026 | Millennium Group Management LLC | Passiv (13G) | 5,50 % | 1.008.662 | +5,50 pp | |
| 10.02.2026 | Integrated Core Strategies (US) LLC | Passiv (13G) | 5,40 % | 997.577 | +5,40 pp | |
| 10.02.2026 | Millennium Management LLC | Passiv (13G) | 5,50 % | 1.008.662 | +5,50 pp | |
| 29.01.2026 | Michael Cho | Passiv (13G/A) | 8,60 % | 1.713.092 | Neu | |
| 29.01.2026 | Affinity Asset Advisors, LLC | Passiv (13G/A) | 8,60 % | 1.713.092 | +0,77 pp |
Stammdaten
Karyopharm Therapeutics Inc., ein Pharmaunternehmen in der Kommerzialisierungsphase, entdeckt, entwickelt und vermarktet Wirkstoffe gegen den Kernexport zur Behandlung von Krebs und anderen Erkrankungen. Das Unternehmen entdeckt, entwickelt und vermarktet neuartige selektive Inhibitoren des Kernexports (SINE-Verbindungen), die durch Bindung an und Hemmung des Kernexportproteins XPO1 funktionieren. Sein Leitpräparat ist XPOVIO in Kombination mit Bortezomib und Dexamethason zur Behandlung erwachsener Patienten mit multiplem Myelom, in Kombination mit Dexamethason zur Behandlung erwachsener Patienten mit intensiv vortherapiertem multiplem Myelom und zur Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom. Das Unternehmen hat eine Lizenzvereinbarung mit der Menarini Group zur Entwicklung und Vermarktung von NEXPOVIO für onkologische Indikationen beim Menschen in Europa, einschließlich des Vereinigten Königreichs, Lateinamerika und anderen Ländern. Seine oralen SINE-Verbindungen sollen auch die Kernakkumulation mehrerer Tumorsuppressor- und Wachstumsproteinen forcieren. Das Unternehmen wurde 2008 gegründet und hat seinen Hauptsitz in Newton, Massachusetts.
Unternehmen & Branche
| Name | Karyopharm Therapeutics Inc. |
|---|---|
| Ticker | KPTI |
| CIK | 0001503802 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 48576U106 |
|---|---|
| ISIN | US48576U1060 |
| Typ | Common Stock |
| Marktkapitalisierung | 166,5 Mio. USD |
| Beta | 0,80 |
Bewertung
| KUV (P/S) | 1,14 vs. 34,76 (2021) ▼ |
|---|---|
| FCF-Rendite | -45,3 % vs. -1,5 % (2021) ▼ |
Qualität & Bilanz
| Operative Marge | -62,1 % vs. -46,8 % (2021) ▼ |
|---|---|
| Nettomarge | -134,2 % vs. -59,1 % (2021) ▼ |
| Zinsdeckungsgrad | -2,0 vs. -3,8 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KUV (P/S) | 34,76 | 36,76 | 10,21 | 0,59 | 0,92 | |
| FCF-Rendite | -1,5 % | -2,6 % | -6,2 % | -149,6 % | -55,9 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | -46,8 % | -90,5 % | -88,7 % | -82,2 % | -62,1 % | |
| Nettomarge | -59,1 % | -105,2 % | -98,0 % | -52,6 % | -134,2 % | |
| Zinsdeckungsgrad | -3,8 | -5,7 | -5,4 | -3,2 | -2,0 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 35.066.000 | -22.392.000 | -1,24 | 131.417.000 | -265.646.000 |
| 2025-12-31 | 10-K | 146.067.000 | -196.039.000 | -17,93 | 108.416.000 | -292.926.000 |
| 2025-09-30 | 10-Q | 44.044.000 | -33.127.000 | -3,82 | 96.232.000 | -269.258.000 |
| 2025-06-30 | 10-Q | 37.929.000 | -37.252.000 | -4,32 | 104.879.000 | -238.926.000 |
| 2025-03-31 | 10-Q | 30.015.000 | -23.462.000 | -2,77 | 127.711.000 | -205.884.000 |
| 2024-12-31 | 10-K | 145.237.000 | -76.422.000 | -0,93 | 164.418.000 | -186.017.000 |
| 2024-09-30 | 10-Q | 38.783.000 | -32.072.000 | -0,26 | 189.476.000 | -159.647.000 |
| 2024-06-30 | 10-Q | 42.786.000 | 23.792.000 | -0,20 | 213.977.000 | -132.140.000 |
| 2024-03-31 | 10-Q | 33.126.000 | -37.362.000 | -0,32 | 204.458.000 | -168.955.000 |
| 2023-12-31 | 10-K | 146.033.000 | -143.099.000 | -1,25 | 240.438.000 | -136.206.000 |
| 2023-09-30 | 10-Q | 36.009.000 | -34.506.000 | -0,30 | 269.960.000 | -100.396.000 |
| 2023-06-30 | 10-Q | 37.579.000 | -32.630.000 | -0,29 | 297.830.000 | -71.248.000 |
| 2023-03-31 | 10-Q | 38.698.000 | -34.126.000 | -0,30 | 325.800.000 | -45.174.000 |
| 2022-12-31 | 10-K | 157.074.000 | -165.291.000 | -2,02 | 358.172.000 | -16.656.000 |
| 2022-09-30 | 10-Q | 36.145.000 | -36.324.000 | -0,45 | 231.236.000 | -140.280.000 |
| 2022-06-30 | 10-Q | 39.679.000 | -49.062.000 | -0,62 | 256.478.000 | -116.338.000 |
| 2022-03-31 | 10-Q | 47.670.000 | -41.399.000 | -0,53 | 294.033.000 | -83.079.000 |
| 2021-12-31 | 10-K | 209.819.000 | -124.088.000 | -1,65 | 305.305.000 | -79.673.000 |
| 2021-09-30 | 10-Q | 37.689.000 | -51.812.000 | -0,69 | 254.094.000 | -125.977.000 |
| 2021-06-30 | 10-Q | 22.601.000 | -53.582.000 | -0,71 | 286.567.000 | -83.132.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 114,9 Mio. | 112,8 Mio. | 112,0 Mio. | 120,4 Mio. | 98,4 Mio. | 78,6 % | +1,8% | |
| License And Other | 31,2 Mio. | 32,4 Mio. | 34,0 Mio. | 36,6 Mio. | 111,4 Mio. | 21,4 % | -3,8% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 14.05.2026 | 35,1 Mio. USD | -1,24 |
| Q3 2025 | 30.09.2025 | 03.11.2025 | 44,0 Mio. USD | -3,82 |
| Q2 2025 | 30.06.2025 | 11.08.2025 | 37,9 Mio. USD | -4,32 |
| Q1 2025 | 31.03.2025 | 14.05.2026 | 30,0 Mio. USD | -2,77 |
| Q3 2024 | 30.09.2024 | 03.11.2025 | 38,8 Mio. USD | -3,85 |
| Q2 2024 | 30.06.2024 | 11.08.2025 | 42,8 Mio. USD | -2,97 |
| Q1 2024 | 31.03.2024 | 12.05.2025 | 33,1 Mio. USD | -4,85 |
| Q3 2023 | 30.09.2023 | 05.11.2024 | 36,0 Mio. USD | -0,30 |
| Q2 2023 | 30.06.2023 | 06.08.2024 | 37,6 Mio. USD | -0,29 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 14.05.2026 | 10-Q | – | – | SEC » |
| 13.02.2026 | 10-K | 31.12.2025 | 44 Tage | SEC » |
| 03.11.2025 | 10-Q | 30.09.2025 | 34 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 12.05.2025 | 10-Q | 31.03.2025 | 42 Tage | SEC » |
| 19.02.2025 | 10-K | 31.12.2024 | 50 Tage | SEC » |
| 05.11.2024 | 10-Q | 30.09.2024 | 36 Tage | SEC » |
| 06.08.2024 | 10-Q | 30.06.2024 | 37 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 02.08.2023 | 10-Q | 30.06.2023 | 33 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 17.02.2023 | 10-K | 31.12.2022 | 48 Tage | SEC » |
| 03.11.2022 | 10-Q | 30.09.2022 | 34 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 01.03.2022 | 10-K | 31.12.2021 | 60 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 04.05.2021 | 10-Q | 31.03.2021 | 34 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 02.11.2020 | 10-Q | 30.09.2020 | 33 Tage | SEC » |
| 04.08.2020 | 10-Q | 30.06.2020 | 35 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (28.05.2026)
HOCH Abgang Schlüsselpersonen (28.05.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 11.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |